Treatment of benign prostatic hyperplasia and erectile dysfunction with tadalafil in the general practice Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2020
DOI: https://doi.org/10.24292/01.MF.0420.20
Keywords:
benign prostatic hyperplasia, erectile dysfunction, tadalafil, treatment

Main Article Content

Kajetan Juszczak
1. Klinika Urologii Ogólnej i Onkologicznej, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; Uniwersytet Mikołaja Kopernika w Toruniu, Szpital Uniwersytecki nr 1 im. dr. Antoniego Jurasza w Bydgoszczy. 2. Oddział Urologii, Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
Tomasz Drewa
1. Klinika Urologii Ogólnej i Onkologicznej, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; Uniwersytet Mikołaja Kopernika w Toruniu, Szpital Uniwersytecki nr 1 im. dr. Antoniego Jurasza w Bydgoszczy. 2 . Oddział Urologii Ogólnej i Onkologicznej, Specjalistyczny Szpital Miejski im. Mikołaja Kopernika w Toruniu

Abstract

Lower urinary tract symptoms and benign prostatic hyperplasia are extremely common in aging men. Recently, more and more attention has been paid to the relationship between LUTS symptoms and erectile dysfunction, because LUTS and ED are very common and often coexist in the same group of aging men (especially after the age of 50) and have significant impact on overall quality of life. Phosphodiesterase 5 (PDE5-i) inhibitors have been used in the treatment of LUTS in the course of BPH, and primarily in the treatment of ED. PDE5-i can be used in patients with moderate or severe LUTS symptoms in the course of BPH with or without ED. Although clinical trials of several selective oral PDE5Is have been performed in men with LUTS, only tadalafil 5 mg once daily has been approved for the treatment of male LUTS. Clinical observations to date indicate that younger men with a low body mass index and more severe LUTS symptoms benefit most from PDE5-i treatment. Long-term experience with the use of tadalafil in men with LUTS is limited to one clinical trial with one year follow-up, therefore no conclusions on its efficacy or tolerance beyond one year are possible.

Article Details

How to Cite
Juszczak , K., & Drewa, T. (2020). Treatment of benign prostatic hyperplasia and erectile dysfunction with tadalafil in the general practice. Medycyna Faktow (J EBM), 13(4(49), 508-513. https://doi.org/10.24292/01.MF.0420.20
Issue
Vol 13 No 4(49) (2020)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms Secondary to BPH. Eur Urol. 2005; 47: 838-45.
2. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep. 2004; 5(4): 251-7.
3. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the ‘‘Cologne Male Survey’’. Int J Impotence Res. 2000; 12: 305-11.
4. Nicolosi A, Moreira ED Jr, Shirai M et al. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003; 61: 201-6.
5. Takeda M, Tang R, Shapiro E et al. Effects of nitric oxide on human and canine prostates. Urology. 1995; 45(3): 440-6.
6. Guh JH, Hwang TL, Ko FN et al. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol. 1998; 53(3): 467-74.
7. Tarcan T, Azadzoi KM, Siroky MB et al. Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J Urol. 1998; 82(suppl 1): 26-33.
8. Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol. 2014; 6(4): 135-47.
9. Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012; 61: 917-25.
10. Oelke M, Shinghal R, Sontag A et al. Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol. 2015; 193: 1581-9.
11. Vlachopoulos C, Oelke M, Maggi M et al. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. Int J Clin Pract. 2015; 69: 1496-507.
12. Gacci M, Salvi M, Sebastianelli A et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol. 2013; 5: 99-111.
13. Donatucci CF, Brock GB, Goldfischer ER et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011; 107: 1110-6.
14. Gacci M, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012; 61: 994-1003.
15. Casabe A, Roehrborn CG, Da Pozzo LF et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014; 191: 727-33.
16. Porst H, Oelke M, Goldfischer ER et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013; 82: 667-73.